Prague Med. Rep. 2016, 117, 129-134

https://doi.org/10.14712/23362936.2016.14

Bone Metabolism of the Patient with a Malignant Melanoma during the Entry Examination and the Check-up of Whole-body Bone Scintigraphy

Jaroslav Weissensteiner1, Eva Babušíková2

1Department of Nuclear Medicine, Hospital Poprad, Poprad, Slovakia
2Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia

Received May 24, 2016
Accepted September 2, 2016

References

1. Biver, E. (2012) Use of bone turnover markers in clinical practice. Curr. Opin. Endocrinol. Diabetes Obes. 19, 468–473. <https://doi.org/10.1097/MED.0b013e3283591492>
2. Brenner, A. I., Koshy, J., Morey, J., Lin, C., DiPoce, J. (2012) The bone scan. Semin. Nucl. Med. 42, 11–26. <https://doi.org/10.1053/j.semnuclmed.2011.07.005>
3. Brountzos, E., Panagiotou, I., Bafaloukos, D., Kelekis, D. (2001) Bone metastases from malignant melanoma: a retrospective review and analysis of 28 cases. Radiol. Oncol. 35, 209–214.
4. Deepali, J., Tejindar, S., Naresh, K., Mradul, K. D. (2007) Metastatic malignant melanoma in bone marrow with occult primary site – a case report with review of literature. Diagn. Pathol. 2, 38.
5. des Grottes, J. M., Dumon, J. C., Body, J. J. (2001) Hypercalcaemia of melanoma: incidence, pathogenesis and therapy with bisphosphonates. Melanoma Res. 11, 477–482. <https://doi.org/10.1097/00008390-200110000-00006>
6. Dummer, R., Hauschild, A., Guggenheim, M., Keilholz, U., Pentheroudakis, G. (2012) Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23, 86–91 (Suppl. 7). <https://doi.org/10.1093/annonc/mds229>
7. Escudero, J. M., Auge, J. M., Filella, X., Torne, A., Pahisa, J., Molina, R. (2011) Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant disease. Clin. Chem. 57, 1534–1544. <https://doi.org/10.1373/clinchem.2010.157073>
8. Garber, M. E., Troyanskaya, O. G., Schluens, K., Petersen, S., Thaesler, Z., Pacyna-Gengelbach, M., van de Rijn, M., Rosen, G. D., Perou, C. M., Whyte, R. I., Altman, R. B., Brown, P. O., Botstein, D., Petersen, I. (2001) Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl. Acad. Sci. U. S. A. 98, 13784–13789. <https://doi.org/10.1073/pnas.241500798> <PubMed>
9. Ghosh, P. (2014) The role of SPECT/CT in skeletal malignancies. Semin. Musculoskelet. Radiol. 18, 175–193.
10. Hasanbegovic, L., Alicelebic, S., Sljivo, N. (2015) Comparison of specific ovarian tumor markers by Elecsys Analyzer 2010. Acta Inform. Med. 23, 86–89. <https://doi.org/10.5455/aim.2015.23.86-89> <PubMed>
11. Iwahori, K., Suzuki, H., Kishi, Y., Fujii, Y., Uehara, R., Okamoto, N., Kobayashi, M., Hirashima, T., Kawase, I., Naka, T. (2012) Serum HE4 as a diagnostic and prognostic marker for lung cancer. Tumour Biol. 33, 1141–1149. <https://doi.org/10.1007/s13277-012-0356-9>
12. Kane, T., Kulshrestha, R., Notghi, A., Elias, M. (2013) Clinical utility (applications) of SPECT/CT. In: Practical SPECT/CT in Nuclear Medicine. Jones, D. W., Hogg, P., Seeram, E., Editors, pp. 165–226, Springer-Verlag, London.
13. Kardamakis, D., Vassiliou, V., Chow, E. (2009) Bone Metastases. A Translational and Clinical Approach. Springer Science + Business Media B. V., Dordrecht.
14. Karlsen, N. S., Karlsen, M. A., Hogdall, C. K., Hogdall, E. V. (2014) HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review. Cancer Epidemiol. Biomarkers Prev. 23, 2285–2295. <https://doi.org/10.1158/1055-9965.EPI-14-0447>
15. Koh, H. K., Sinks, T. H., Geller, A. C., Miller, D. R., Lew, R. A. (1993) Etiology of melanoma. Cancer Treat. Res. 65, 1–28. <https://doi.org/10.1007/978-1-4615-3080-0_1>
16. Li, J., Chen, H., Mariani, A., Chen, D., Klatt, E., Podratz, K., Drapkin, R., Broaddus, R., Dowdy, S., Jiang, S. W. (2013) HE4 (WFDC2) promotes tumor growth in endometrial cancer cell lines. Int. J. Mol. Sci. 14, 6026–6043. <https://doi.org/10.3390/ijms14036026> <PubMed>
17. O’Neal, R. L., Nam, K. T., LaFleur, B. J., Barlow, B., Nozaki, K., Lee, H. J., Kim, W. H., Yang, H. K., Shi, C., Maitra, A., Montgomery, E., Washington, M. K., El Rifai, W., Drapkin, R. I., Goldering, J. R. (2013) Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas. Hum. Pathol. 44, 734–742. <https://doi.org/10.1016/j.humpath.2012.07.017> <PubMed>
18. Potepan, P., Spagnoli, I., Danesini, G. M., Laffranchi, A., Gadda, D., Mascheroni, L., Guzzon, A. (1994) The radiodiagnosis of bone metastases from melanoma. Radiol. Med. 87, 741–746.
19. Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltharn, M., Pergamenschikov, A., Lee, J. C., Lashkari, D., Shalon, D., Myers, T. G., Weinstein, J. N., Botstein, D., Brown, P. O. (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24, 227–235. <https://doi.org/10.1038/73432>
20. Ryu, B., Jones, J., Blades, N. J., Parmigiani, G., Hollingsworth, M. A., Hruban, R. H., Kern, S. E. (2002) Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res. 62, 819–826.
21. Serrier, C., Lesesve, J. F. (2013) Metastatic malignant melanoma in the bone marrow. Blood 121, 721. <https://doi.org/10.1182/blood-2012-09-454546>
22. Zbytek, B., Carlson, J. A., Granese, J., Ross, J., Mihm, M. C., Slominski, A. (2008) Current concepts of metastasis in melanoma. Expert Rev. Dermatol. 3, 569–585. <https://doi.org/10.1586/17469872.3.5.569> <PubMed>
front cover

ISSN 1214-6994 (Print) ISSN 2336-2936 (Online)

Archive